Spirit Airlines Seeks Court Approval to Auction 20 Airbus A320/A321 Aircraft Amid Bankruptcy 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
ANZ Shares Hit Record High After Strong Q1 Profit and Cost-Cutting Gains 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
Russia Signals Further Restrictions on Telegram Amid Ongoing Regulatory Disputes 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Petrobras Posts Record Oil Exports as Production Surge Fuels Global Expansion 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
Ralph Lauren Unveils Elegant Fall 2026 Women’s Collection Ahead of New York Fashion Week 
BURNABY, British Columbia, Nov. 08, 2017 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's President and Chief Executive Officer, will present a corporate update at the Stifel 2017 Healthcare Conference in New York, NY on Tuesday, November 14, 2017 at 2:00 pm ET.
A live audio webcast of the presentation will be available on the investors section of Xenon's website at www.xenon-pharma.com and will be available for replay following the event.
About Xenon Pharmaceuticals Inc.
Xenon is a clinical stage biopharmaceutical company focused on developing innovative therapeutics to improve the lives of patients with neurological disorders. Building upon our extensive knowledge of human genetics and diseases caused by mutations in ion channels, known as channelopathies, we are advancing – both independently and with our pharmaceutical collaborators – a novel product pipeline of ion channel modulators to address therapeutic areas of high unmet medical need, such as pain and epilepsy. For more information, please visit www.xenon-pharma.com.
Investor/Media Contact:
Jodi Regts
VP, Corporate Affairs & Investor Relations
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]
